跳至主要内容
临床试验/EUCTR2017-001406-15-ES
EUCTR2017-001406-15-ES进行中(未招募)1 期

Adequate duration of antibiotic treatment in community acquired pneumonia categorized by pneumonia severity index (PSI)

Fundació Clínic per la Recerca Biomèdica0 个研究点目标入组 424 人开始时间: 2018年4月9日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
424

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1) Hospitalized patients diagnosed with Community Acquired Pneumonia: appearance of a new radiological infiltrate plus the presence of at least two of the following signs or symptoms: fever (> 38 ºC), cough, expectoration, chest pain, dyspnea or tachypnea, and signs of occupation of the alveolar space.
  • 2) A PSI score class IV or V.
  • 3) Patients who have received adequate antibiotic treatment according to clinical guidelines from the first hour of emergency room admission.
  • 4) Patients who achieve clinical stability: temperature =37.2 ºC, heart rate =100 beats / min, respiratory rate =24 breaths / min, systolic blood pressure> 90 mmHg; oxygen saturation> 90%; or oxygen blood pressure> 60 mmHg (15) before the fourth day.
  • 5) Signature of informed consent.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 212
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 212

排除标准

  • 1) Immunosuppression: Coinfection with HIV and presence of AIDS, neutropenic or have received immunosuppressive treatment for any cause. Patients with chronic use of corticosteroids (prednisone or its equivalent)> 10 mg / day for 14 days.
  • 2) Patients hospitalized in the previous 14 days.
  • 3) Suspected multi-resistant germs of any cause.
  • 4) Hypersensitivity or alterations in the tendons associated with the fuoroquinolones.
  • 5) Pregnancy or lactation

研究者

发起方
Fundació Clínic per la Recerca Biomèdica

相似试验

Assess the optimal duration of pneumonia antibiotic... | 临床试验